AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)

Rolof G.P. Gijtenbeek; Vincent van der Noort; Joachim G. J. V. Aerts; Jeske A. Staal-Van Den Brekel; Egbert F. Smit; Frans H. Krouwels; Frank A. Wilschut; T. Jeroen N. Hiltermann; Wim Timens; Ed Schuuring; Joost D.J. Janssen; Martijn Goosens; Paul M. van den Berg; A. Joop de Langen; Jos A. Stigt; Ben E. E. M. van den Borne; Harry J. M.  Groen; Wouter H. van Geffen; Anthonie J. van der Wekken

doi:10.1183/23120541.50239-2022

AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)

Rolof G.P. Gijtenbeek
, Vincent van der Noort
, Joachim G. J. V. Aerts
, Jeske A. Staal-Van Den Brekel
, Egbert F. Smit
, Frans H. Krouwels
, Frank A. Wilschut
, T. Jeroen N. Hiltermann
, Wim Timens
, Ed Schuuring
, Joost D.J. Janssen
, Martijn Goosens
, Paul M. van den Berg
, A. Joop de Langen
, Jos A. Stigt
, Ben E. E. M. van den Borne
, Harry J. M. Groen
, Wouter H. van Geffen
, Anthonie J. van der Wekken

Onderzoeksoutput

Originele taal-2	English
Artikelnummer	50239-2022
Tijdschrift	ERJ Open Research
Volume	10
Nummer van het tijdschrift	1
DOI's	https://doi.org/10.1183/23120541.50239-2022
Status	Published - 1-jan-2024

Toegang tot document

10.1183/23120541.50239-2022Licentie: CC BY-NC

Handle.net

Permanente koppeling

Andere bestanden en links

Link naar publicatie in Scopus

1 Article

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
Gijtenbeek, R. G. P., van der Noort, V., Aerts, J. G. J. V., Staal-Van Den Brekel, J. A., Smit, E. F., Krouwels, F. H., Wilschut, F. A., Hiltermann, T. J. N., Timens, W., Schuuring, E., Janssen, J. D. J., Goosens, M., van den Berg, P. M., Joop de Langen, A., Stigt, J. A., van den Borne, B. E. E. M., Groen, H. J. M., van Geffen, W. H. & van der Wekken, A. J., 17-okt-2022, In: ERJ Open Research. 8, 4, 9 blz., 00239-2022.
Onderzoeksoutput: Article › Academic › peer review

Open Access
Bestand
11 Citaten (Scopus)

129 Downloads (Pure)

Citeer dit

Gijtenbeek, R. G. P., van der Noort, V., Aerts, J. G. J. V., Staal-Van Den Brekel, J. A., Smit, E. F., Krouwels, F. H., Wilschut, F. A., Hiltermann, T. J. N., Timens, W., Schuuring, E., Janssen, J. D. J., Goosens, M., van den Berg, P. M., de Langen, A. J., Stigt, J. A., van den Borne, B. E. E. M., Groen, H. J. M., van Geffen, W. H., & van der Wekken, A. J. (2024). AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022). ERJ Open Research, 10(1), Artikel 50239-2022. https://doi.org/10.1183/23120541.50239-2022

@article{1a585e858fea46e99a568fbf38acc683,

title = "AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)",

author = "Gijtenbeek, \{Rolof G.P.\} and \{van der Noort\}, Vincent and Aerts, \{Joachim G. J. V.\} and \{Staal-Van Den Brekel\}, \{Jeske A.\} and Smit, \{Egbert F.\} and Krouwels, \{Frans H.\} and Wilschut, \{Frank A.\} and Hiltermann, \{T. Jeroen N.\} and Wim Timens and Ed Schuuring and Janssen, \{Joost D.J.\} and Martijn Goosens and \{van den Berg\}, \{Paul M.\} and \{de Langen\}, \{A. Joop\} and Stigt, \{Jos A.\} and \{van den Borne\}, \{Ben E. E. M.\} and Groen, \{Harry J. M.\} and \{van Geffen\}, \{Wouter H.\} and \{van der Wekken\}, \{Anthonie J.\}",

year = "2024",

month = jan,

day = "1",

doi = "10.1183/23120541.50239-2022",

language = "English",

volume = "10",

journal = "ERJ Open Research",

issn = "2312-0541",

publisher = "European Respiratory Society",

number = "1",

}

Gijtenbeek, RGP, van der Noort, V, Aerts, JGJV, Staal-Van Den Brekel, JA, Smit, EF, Krouwels, FH, Wilschut, FA, Hiltermann, TJN , Timens, W , Schuuring, E, Janssen, JDJ, Goosens, M, van den Berg, PM, de Langen, AJ, Stigt, JA, van den Borne, BEEM, Groen, HJM, van Geffen, WH & van der Wekken, AJ 2024, 'AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)', ERJ Open Research, vol. 10, nr. 1, 50239-2022. https://doi.org/10.1183/23120541.50239-2022

AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022). / Gijtenbeek, Rolof G.P.; van der Noort, Vincent; Aerts, Joachim G. J. V. et al.
In: ERJ Open Research, Vol. 10, Nr. 1, 50239-2022, 01.01.2024.

Onderzoeksoutput

TY - JOUR

T1 - AUTHOR CORRECTION to

T2 - “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)

AU - Gijtenbeek, Rolof G.P.

AU - van der Noort, Vincent

AU - Aerts, Joachim G. J. V.

AU - Staal-Van Den Brekel, Jeske A.

AU - Smit, Egbert F.

AU - Krouwels, Frans H.

AU - Wilschut, Frank A.

AU - Hiltermann, T. Jeroen N.

AU - Timens, Wim

AU - Schuuring, Ed

AU - Janssen, Joost D.J.

AU - Goosens, Martijn

AU - van den Berg, Paul M.

AU - de Langen, A. Joop

AU - Stigt, Jos A.

AU - van den Borne, Ben E. E. M.

AU - Groen, Harry J. M.

AU - van Geffen, Wouter H.

AU - van der Wekken, Anthonie J.

PY - 2024/1/1

Y1 - 2024/1/1

UR - https://www.scopus.com/pages/publications/85194262441

U2 - 10.1183/23120541.50239-2022

DO - 10.1183/23120541.50239-2022

M3 - Erratum

AN - SCOPUS:85194262441

SN - 2312-0541

VL - 10

JO - ERJ Open Research

JF - ERJ Open Research

IS - 1

M1 - 50239-2022

ER -

Gijtenbeek RGP, van der Noort V, Aerts JGJV, Staal-Van Den Brekel JA, Smit EF, Krouwels FH et al. AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022). ERJ Open Research. 2024 jan 1;10(1):50239-2022. doi: 10.1183/23120541.50239-2022

AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)

Toegang tot document

Handle.net

Andere bestanden en links

Onderzoekersoutput

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Citeer dit